Working inthe area of Bioproduction Solutions for next-generation medicines, XDemics is structured around eliminating the production bottlenecks that can interrupt ready patient access to next-generation medicines: Viral Gene Therapy, Oncolytics, Antibody, Cell Therapy andVaccines. With the firm's team incuding surgical oncologists, gene therapy pioneers, microfabrication professors, bioprocess engineers, and operations experts the firm's effort is to getting the product made right. With expertise in adapting cell and viral production to intensified processes - utilizing the firm's proprietary bioreactor technology - whether based on suspension or adherent cells, replication competent or incompetent viruses, first-generation or latest generation vectors, Xdemics aleaites the problem of production bottlenecks. The firm's high density cell respirator technology (HDCR) allows unparalleled intensification and predictable scalability of the most challenging bioproduction processes - radically improving production logistics and economics by saving on space, time, labor, and feedstock."
